




Supplementary materials




Supplementary Figure 1. Inhibition of PLK1 delays TNBC tumor growth in vivo. (A-C) Knockdown of PLK1 in MDA-MB-231 cells delayed tumor growth in vivo. PLK1 knockdown MDA-MB-231 cells and their control cells were subcutaneously injected into the flanks of 6-week old nude mice (4×10^6 cells per mouse). (B) The volume of each tumor was measured every week. The average ($n = 5$) tumor volume (\pm SD) in each group of mice was calculated, * $p < 0.05$. (C) After four weeks, mice were sacrificed and mean tumor weight (\pm SD) was calculated in each group, * $p < 0.05$. (D-F) Volasertib inhibits TNBC tumor growth in vivo. MDA-MB-231 cells were subcutaneously injected into the flanks of 6-week old nude mice (4×10^6 cells per mouse). After tumors grew to about 100 mm³, mice were treated intraperitoneally with indicated dose of volasertib, twice a week for 30 days. (D) Representative tumor images of each group of mice. (E) The volume of each tumor was measured every week. The average ($n = 5$) tumor volume (\pm SD) in each group of mice was calculated, * $p < 0.05$. (F) After four weeks treatment, mice were sacrificed and mean tumor weight (\pm SD) was calculated in each group, * $p < 0.05$.



Supplementary Figure 2. Synergistic inhibition of cell viability by olaparib and volasertib in MDA-MB-231 cells. MDA-MB-231 cells were treated with various combinations of volasertib and olaparib for 48 h and dose effect (A) and Fractional effect (B) graphs were generated using Calcsyn software. (C) Combination Index (CI) were calculated using Chou and Talalay method.



Supplementary Figure 3. Synergistic inhibition of cell viability by olaparib and volasertib in CAL-51 cells. CAL-51 cells were treated with various combinations of volasertib and olaparib for 48 h and dose effect (A) and Fractional effect (B) graphs were generated using Calcosyn software. (C) Combination Index (CI) were calculated using Chou and Talalay method.



Supplementary Figure 4. Synergistic inhibition of cell viability by olaparib and volasertib in CAL-120 cells. Cal-120 cells were treated with various combinations of volasertib and olaparib for 48 h and dose effect (A) and Fractional effect (B) graphs were generated using Calcosyn software. (C) Combination Index (CI) were calculated using Chou and Talalay method.